Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:KMPH

Zevra Therapeutics (KMPH) Stock Price, News & Analysis

Zevra Therapeutics logo

About Zevra Therapeutics Stock (NASDAQ:KMPH)

Advanced Chart
Remove Ads

Key Stats

Today's Range
N/A
50-Day Range
$4.48
$6.27
52-Week Range
N/A
Volume
64,100 shs
Average Volume
189,500 shs
Market Capitalization
$200.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

KemPharm, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses on the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Remove Ads
Receive KMPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zevra Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

KMPH Stock News Headlines

Zevra Therapeutics price target raised to $25 from $23 at Canaccord
Zevra Therapeutics price target raised to $22 from $20 at Guggenheim
Three new patents reveal Elon and Trump’s secret “Project America”
Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR! He says these 5 stocks are trading for less than $2 right now… But they could soon SOAR in Trump’s first 100 days.
Zevra Therapeutics reports Q4 EPS (67c), consensus (40c)
Zevra Therapeutics to sell Rare Pediatric Disease PRV for $150M
Zevra Therapeutics (ZVRA) Gets a Buy from Roth MKM
Zevra Therapeutics price target raised to $21 from $20 at Guggenheim
See More Headlines

KMPH Stock Analysis - Frequently Asked Questions

Zevra Therapeutics, Inc. (NASDAQ:KMPH) issued its quarterly earnings results on Wednesday, March, 30th. The specialty pharmaceutical company reported ($0.08) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.08). Zevra Therapeutics had a negative trailing twelve-month return on equity of 16.12% and a negative net margin of 328.56%.

Zevra Therapeutics (KMPH) raised $60 million in an initial public offering (IPO) on Thursday, April 16th 2015. The company issued 4,600,000 shares at a price of $12.00-$14.00 per share. Cowen and Company and RBC Capital Markets served as the underwriters for the IPO and Canaccord Genuity and Oppenheimer were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Zevra Therapeutics investors own include Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Meta Platforms (META), SCYNEXIS (SCYX), BioCryst Pharmaceuticals (BCRX), Zoom Video Communications (ZM) and TherapeuticsMD (TXMD).

Company Calendar

Last Earnings
3/30/2022
Today
4/04/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:KMPH
Employees
22
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-8,560,000.00
Net Margins
-328.56%
Pretax Margin
-335.26%

Debt

Sales & Book Value

Annual Sales
$10.72 million
Price / Cash Flow
23.28
Book Value
$3.63 per share
Price / Book
N/A

Miscellaneous

Free Float
34,125,000
Market Cap
$200.47 million
Optionable
Optionable
Beta
2.16

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:KMPH) was last updated on 4/4/2025 by MarketBeat.com Staff
From Our Partners